M
Michael Kolinsky
Researcher at University of Alberta
Publications - 40
Citations - 721
Michael Kolinsky is an academic researcher from University of Alberta. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 10, co-authored 25 publications receiving 421 citations. Previous affiliations of Michael Kolinsky include Institute of Cancer Research & Alberta Health Services.
Papers
More filters
Journal ArticleDOI
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg,Karim Fizazi,Fred Saad,N. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel I.G. Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain +17 more
TL;DR: Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgens-depRIvation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.
Journal ArticleDOI
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
Joaquin Mateo,Joaquin Mateo,Heather H. Cheng,Heather H. Cheng,Himisha Beltran,David Dolling,Wen Xu,Colin C. Pritchard,Colin C. Pritchard,Helen Mossop,Pasquale Rescigno,Pasquale Rescigno,Raquel Perez-Lopez,Raquel Perez-Lopez,Verena Sailer,Michael Kolinsky,Michael Kolinsky,Ada Balasopoulou,Claudia Bertan,David M. Nanus,Scott T. Tagawa,Heather Thorne,Heather Thorne,Bruce Montgomery,Bruce Montgomery,Suzanne Carreira,Shahneen Sandhu,Mark A. Rubin,Mark A. Rubin,Peter S. Nelson,Peter S. Nelson,Johann S. de Bono,Johann S. de Bono +32 more
TL;DR: Pritchard et al. as discussed by the authors found that patients with inherited DNA repair mutations appeared to benefit from standard therapies similarly to the overall population; prospective studies are ongoing to investigate the impact of PARPi/platinum.
Journal ArticleDOI
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Adam Sharp,Jon Welti,Maryou B K Lambros,David Dolling,Daniel Nava Rodrigues,Lorna Pope,Caterina Aversa,Ines Figueiredo,Jennifer Fraser,Zai Ahmad,Changxue Lu,Pasquale Rescigno,Pasquale Rescigno,Michael Kolinsky,Claudia Bertan,George Seed,Ruth Riisnaes,Susana Miranda,Mateus Crespo,Rita Pereira,Ana Ferreira,Gemma Fowler,Berni Ebbs,Penny Flohr,Antje Neeb,Diletta Bianchini,Antonella Petremolo,Semini Sumanasuriya,Alec Paschalis,Joaquin Mateo,Nina Tunariu,Wei Yuan,Suzanne Carreira,Stephen R. Plymate,Jun Luo,Johann S. de Bono +35 more
TL;DR: Liquid biopsies that determine circulating tumour cell androgen receptor splice variant-7 status have the potential to impact treatment decisions in metastatic castration-resistant prostate cancer patients and robust clinical qualification of these assays is required before their routine use.
Journal ArticleDOI
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
Pasquale Rescigno,David Lorente,Diletta Bianchini,Roberta Ferraldeschi,Michael Kolinsky,Spyridon Sideris,Zafeiris Zafeiriou,Semini Sumanasuriya,Alan D. Smith,Niven Mehra,Anuradha Jayaram,Raquel Perez-Lopez,Joaquin Mateo,Chris Parker,David P. Dearnaley,Nina Tunariu,Alison Reid,Gerhardt Attard,Johann S. de Bono +18 more
TL;DR: Patients not achieving 30% PSA decline after 4 wk of AA have a lower likelihood of achieving PSA response at 12 wk and significantly inferior OS, and early PSA changes are associated with survival in patients receiving abiraterone acetate.
Journal ArticleDOI
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
Michael Kolinsky,Michael Kolinsky,Michael Kolinsky,Pasquale Rescigno,Pasquale Rescigno,Diletta Bianchini,Diletta Bianchini,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Niven Mehra,Niven Mehra,Joaquin Mateo,Joaquin Mateo,Vasiliki Michalarea,Vasiliki Michalarea,Ruth Riisnaes,Mateus Crespo,Ines Figueiredo,Susana Miranda,D. Nava Rodrigues,Penny Flohr,Nina Tunariu,Nina Tunariu,Udai Banerji,Udai Banerji,Ruth Ruddle,Adam Sharp,Adam Sharp,Jonathan Welti,Maryou B. Lambros,Suzanne Carreira,Florence I. Raynaud,Karen E Swales,Stephen R. Plymate,Jun Luo,Holly Tovey,Nuria Porta,Rachel Slade,Lorna Leonard,Emma Hall,J.S. de Bono,J.S. de Bono +41 more
TL;DR: The combination of capivasertib and enzalutamide is tolerable and has antitumour activity, with all responding patients harbouring aberrations in the PI3K/AKT/mTOR pathway.